Experience of Adolescents With Anorexia Nervosa Towards Antidepressants (E3A)

September 5, 2025 updated by: Assistance Publique - Hôpitaux de Paris

Subjective Experience of Adolescents Suffering From Anorexia Nervosa With Antidepressants

The purpose of this study is to explore the experience of adolescents suffering from anorexia nervosa confronted with the prescription of antidepressants

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In our adolescent psychiatric unit, antidepressant's prescription is common during the care pathway for adolescents with anorexia nervosa.

The literature highlights a paradox between scientific data and clinical practice, based on expert consensus. There are a very few qualitative studies in this subject and none of them concern adolescents.

The purpose of this qualitative study is to explore the experience and opinion of adolescents suffering from anorexia nervosa confronted with the prescription of antidepressants

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris, France, 75014
        • Maison de Solenn / Cochin Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 25 years (Child, Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents (between 12 and 25 years) suffer from anorexia nervosa, at the Maison de Solenn, Cochin Hospital, Paris, France

Description

Inclusion Criteria:

  • Adolescents aged 12 to 25
  • Suffering from anorexia nervosa [according to DSM-5 criteria]
  • Has been prescribed for a type of SSRIs antidepressant (still ongoing or interrupted at the time of the interview)
  • Non-opposition to the study

Exclusion Criteria:

  • Atypical eating disorder that do not meet DSM-5 criteria for restrictive anorexia nervosa
  • Body Mass Index < 15
  • Prescribed for another antidepressant than SSRIs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Adolescents with anorexia nervosa
Adolescents from 12 to 25 year old, cared for anorexia nervosa at the Maison de Solenn (Cochin hospital, Paris, France) et for whom antidepressive agents have been prescribed
Other: Survey
Oral interview and written questions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Qualitative data / Experience of taking anidepressants
Time Frame: At the time of inclusion (Day 0)
Subjective experience of adolescents with anorexia nervosa about prescription of antidepressants and their effects will be obtained during the grid interview and through their describing to written questions
At the time of inclusion (Day 0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

URC Necker Cochin, France

Investigators

  • Principal Investigator: Maude LUDOT, Psychiatrist, APHP, Hôpital Cochin, Maison de Solenn, F-75014 Paris, France
  • Study Chair: Marie-Rose MORO, PU-PH, APHP, Hôpital Cochin, Maison de Solenn, F-75014 Paris, France
  • Study Director: Corinne BLANCHET, PH, APHP, Hôpital Cochin, Maison de Solenn, F-75014 Paris, France
  • Study Director: Jonathan LACHAL, PHU, APHP, Hôpital Cochin, Maison de Solenn, F-75014 Paris, France

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 31, 2020

Primary Completion (Actual)

October 20, 2020

Study Completion (Actual)

October 20, 2020

Study Registration Dates

First Submitted

July 17, 2020

First Submitted That Met QC Criteria

July 17, 2020

First Posted (Actual)

July 22, 2020

Study Record Updates

Last Update Posted (Estimated)

September 12, 2025

Last Update Submitted That Met QC Criteria

September 5, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • APHP200104

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

  • Use of a treatment database, named Actipidos
  • Interview recording on a Dictaphone [kept all over the study in a locked drawer in a medical office at the Maison de Solenn, and then destroyed].
  • Verbatim transcription, on a word-formatted file from a computer in a medical office at the Maison de Solenn; computer secured by a password.
  • Transcripts will be anonymized with an identical number as soon as they are created; no non-anonymized data records will be kept beyond the end of the study.

IPD Sharing Time Frame

6 months after publication

IPD Sharing Access Criteria

Interviews will be analysed with a qualitative methodology (Interpretative Phenomenological Analysis)

- Emergent themes will be presented.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe